GlassScriptPhysician profile
Josephine Chen
NPI 1790175214
$1,380.42
in general payments reported to CMS, 2019-2025
13 companies · $622 in 2025
The $622 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $422 · 2024: $337 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,380.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $241.39 | 2025 | Korlym |
| Astellas Pharma US INC | $165.85 | 2023-2024 | Veozah |
| Lilly USA, LLC | $154.35 | 2023-2024 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $130.93 | 2023-2025 | Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $128.07 | 2024 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.99 | 2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $121.83 | 2023 | Breztri |
| Dexcom, INC. | $112.79 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Biogen, INC. | $112.00 | 2025 | Zurzuvae |
| Pfizer INC. | $26.21 | 2023 | |
| Genzyme Corporation | $21.87 | 2024 | |
| Novo Nordisk INC | $20.95 | 2024 | Ozempic, Rybelsus |
| Electromed, INC. | $19.19 | 2024 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josephine Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.